![PDF) ESOPEC: Prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286) PDF) ESOPEC: Prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)](https://i1.rgstatic.net/publication/305451496_ESOPEC_Prospective_randomized_controlled_multicenter_phase_III_trial_comparing_perioperative_chemotherapy_FLOT_protocol_to_neoadjuvant_chemoradiation_CROSS_protocol_in_patients_with_adenocarcinoma_of_/links/57cba87e08ae3ac722b1efc0/largepreview.png)
PDF) ESOPEC: Prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286)
![PDF] Cross-trial prediction of treatment outcome in depression: a machine learning approach. | Semantic Scholar PDF] Cross-trial prediction of treatment outcome in depression: a machine learning approach. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/6194c942b91634e8b7c340f158ba759b0789ca7d/5-Figure2-1.png)
PDF] Cross-trial prediction of treatment outcome in depression: a machine learning approach. | Semantic Scholar
![PDF] Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol | Semantic Scholar PDF] Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/630bc6b873bf8304e24a6ac1260e289c3deac5d2/5-Figure1-1.png)
PDF] Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol | Semantic Scholar
![Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer - Mayanagi - 2019 - Annals of Gastroenterological Surgery - Wiley Online Library Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer - Mayanagi - 2019 - Annals of Gastroenterological Surgery - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/64811f34-1de4-4284-97d5-64c51a6d122a/ags312243-fig-0001-m.jpg)
Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer - Mayanagi - 2019 - Annals of Gastroenterological Surgery - Wiley Online Library
![CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in ... CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in ...](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-018-4770-2/MediaObjects/12885_2018_4770_Fig1_HTML.png)
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in ...
![ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286) | BMC Cancer | Full ... ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286) | BMC Cancer | Full ...](https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12885-016-2564-y/MediaObjects/12885_2016_2564_Fig1_HTML.gif)
ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286) | BMC Cancer | Full ...
![Journal of Clinical Oncology on X: "Survival benefit of preoperative chemoradiotherapy for patients with esophageal cancer persists - 10-year outcome of the CROSS trial https://t.co/s02sMVpYhI #esocsm #JCO @ErasmusMC @bmeyck https://t.co/2JwV0iOvoB" / X Journal of Clinical Oncology on X: "Survival benefit of preoperative chemoradiotherapy for patients with esophageal cancer persists - 10-year outcome of the CROSS trial https://t.co/s02sMVpYhI #esocsm #JCO @ErasmusMC @bmeyck https://t.co/2JwV0iOvoB" / X](https://pbs.twimg.com/media/E0o7QqjWQAEy-u9.jpg)
Journal of Clinical Oncology on X: "Survival benefit of preoperative chemoradiotherapy for patients with esophageal cancer persists - 10-year outcome of the CROSS trial https://t.co/s02sMVpYhI #esocsm #JCO @ErasmusMC @bmeyck https://t.co/2JwV0iOvoB" / X
![Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma | British Journal of Cancer Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-023-02458-w/MediaObjects/41416_2023_2458_Figa_HTML.png)
Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma | British Journal of Cancer
![Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity | Strahlentherapie und Onkologie Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity | Strahlentherapie und Onkologie](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00066-020-01594-z/MediaObjects/66_2020_1594_Fig1_HTML.png)
Modification of preoperative radiochemotherapy for esophageal cancer (CROSS protocol) is safe and efficient with no impact on surgical morbidity | Strahlentherapie und Onkologie
![Frontiers | Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial Frontiers | Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial](https://www.frontiersin.org/files/Articles/917961/fonc-12-917961-HTML/image_m/fonc-12-917961-g001.jpg)
Frontiers | Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial
![Real-world Scenario: CROSS Regimen as Preoperative Therapy for Oesophageal Squamous Cell Carcinoma | Journal of Gastrointestinal Surgery Real-world Scenario: CROSS Regimen as Preoperative Therapy for Oesophageal Squamous Cell Carcinoma | Journal of Gastrointestinal Surgery](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11605-020-04704-5/MediaObjects/11605_2020_4704_Fig1_HTML.png)
Real-world Scenario: CROSS Regimen as Preoperative Therapy for Oesophageal Squamous Cell Carcinoma | Journal of Gastrointestinal Surgery
![Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial - The Lancet Oncology Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2113983482/2084460251/gr1.gif)
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial - The Lancet Oncology
![Bennouna Jaafar on X: "From the CROSS trial to CheckMate 577. Need to have OS data in CM577. longer follow-up. And come back more precisely to CPS-PD-L1 data. https://t.co/aUy1dDuxQ1" / X Bennouna Jaafar on X: "From the CROSS trial to CheckMate 577. Need to have OS data in CM577. longer follow-up. And come back more precisely to CPS-PD-L1 data. https://t.co/aUy1dDuxQ1" / X](https://pbs.twimg.com/media/Ex9qAdbWgAQe4-Y.jpg)
Bennouna Jaafar on X: "From the CROSS trial to CheckMate 577. Need to have OS data in CM577. longer follow-up. And come back more precisely to CPS-PD-L1 data. https://t.co/aUy1dDuxQ1" / X
![ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS) | BMC Cancer | Full Text ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS) | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-017-3386-2/MediaObjects/12885_2017_3386_Fig1_HTML.gif)
ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS) | BMC Cancer | Full Text
![The design and evaluation of hybrid controlled trials that leverage external data and randomization | Nature Communications The design and evaluation of hybrid controlled trials that leverage external data and randomization | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-022-33192-1/MediaObjects/41467_2022_33192_Fig1_HTML.png)